Results 201 to 210 of about 1,150,143 (287)

ALDH18A1 regulates glutamine metabolism and tumor microenvironment in the attenuation of clear cell renal cell carcinoma. [PDF]

Cancer Cell Int
Fu Y, Liu X, Sun Q, Tang Z, Xu Z, Liu K.
europepmc   +1 more source

3D Bioprinted Blood–Brain–Tumor Barrier Spheroid‐Based In Situ Evaluation of Anticancer Compounds Against Glioblastoma: ROS‐Producing Ruthenium as a Potential Therapeutic Candidate

Advanced Science, EarlyView.
The blood–brain–tumor barrier (BBTB) penetration by anticancer drugs and their effects on glioblastoma (GBM) is assessed using 3D bioprinted‐spheroids. Anticancer drug‐induced U‐87 MG cell death is quantified through in situ imaging of spheroids using a cancer cell death probe. The Ru compound, a partial P‐gp substrate, induces greater tumor‐cell death
Hyunjung Lee, Chan Ho Jeon, Doyun Kim, Minjae Lee, Minji Kwon, Joon Myong Song   +5 more
wiley   +1 more source

CD90 Promotes Gastric Cancer Progression by Regulating SLC1A5-Mediated Glutamine Metabolism Through YY1. [PDF]

Cancer Sci
Zhou Z, Liu S, Zhang C, Deng J, Liang L, Zhou Y.   +5 more
europepmc   +1 more source

A Novel Reactive Oxygen Species‐Responsive Bone‐Targeted Nanoplatform Based on Cloperastine Attenuates Ovariectomy‐Induced Bone Loss by Inhibiting Osteoclast Oxidative Phosphorylation

Advanced Science, EarlyView.
Cloperastine suppresses osteoclastogenesis by inhibiting PGC1β‐mediated oxidative phosphorylation. Its incorporation into a ROS‐responsive, Asp8‐modified nanoplatform enhances skeletal accumulation. The resulting Clo/Asp8‐PMK‐MCs combine cloperastine‐mediated antiresorptive activity with carrier‐mediated osteogenic activity to attenuate OVX‐induced ...
Haibo Liang, Yong Xiao, Jiangtao Luo, Xiao Yang, Yayun Yang, Qihang Wu, Chenxin Yu, Zhihao Zhou, Xiaoqing Si, Jiansen Miao, Yiting Tu, Qichen Lu, Boreng Qian, Xiangyang Wang, Jiake Xu, Changcan Shi, Haiming Jin   +16 more
wiley   +1 more source

Hypoxia drives ferroptosis resistance and immunosuppression in hepatocellular carcinoma by inducing UBASH3B-mediated glutamine metabolism reprogramming and CXCL8 expression. [PDF]

Redox Biol
Pan GQ, Zhang SP, Wang X, Qu Y, Liu XF, Yan YC, Li T, Dong ZR.   +7 more
europepmc   +1 more source

Glutamine Metabolism in Old Age [PDF]

, 2017
openaire   +3 more sources

Hepatic Lipid Stress Drives Metabolic Dysfunction‐Associated Steatohepatitis Progression through FTO O‐GlcNAcylation‐Induced m6A Demethylation of HRAS

Advanced Science, EarlyView.
Lipid stress drives O‐GlcNAcylation of the m6A demethylase FTO at Ser195, enhancing its stability and demethylase activity. This modification removes m6A from HRAS mRNA, preventing its degradation and activating PI3K/AKT signaling to promote hepatic steatosis and inflammation.
Jia‐Xin Yin, Yan‐Lai Zhang, Qun Liu, Rui Liu, Hai‐Yang Yuan, Sui‐Dan Chen, Ming‐Hua Zheng, Kai Wang, Ni Tang, Ai‐Long Huang   +9 more
wiley   +1 more source

Fueling the Fire: How Glutamine Metabolism Sustains Leukemia Growth and Resistance. [PDF]

BioMed (Basel)
Silvestri G.
europepmc   +1 more source

PDHA1 Hyperactivation‐Mediated Glucose Metabolism Reprogramming Fuels Neutrophil NETosis and Promotes Acute Lung Injury

Advanced Science, EarlyView.
During NETosis, neutrophils shift metabolically toward enhanced OXPHOS and partially reduced glycolysis. This shift is driven by PDHA1 hyperactivity‐dependent selective metabolic reprogramming. The neutrophil‐targeted nanoparticle 3‑FP‑BSA NPs effectively inhibit NETosis and attenuate ALI.
Yu‐Biao Liu, Wen‐Jing Zhong, Chen‐Yu Zhang, Meng‐Rui Chen, Nan‐Shi‐Yu Yang, Han‐Xi Sha, Yan‐Ling Qiu, Hui Chen, Jin‐Tong Yang, Li‐Ying Liang, Jian‐Bing Xiong, Shao‐Kun Liu, Cha‐Xiang Guan, Jia‐Xi Duan, Yong Zhou   +14 more
wiley   +1 more source

Dual targeting of glutamine metabolism and lysosomal function in eliminating drug-tolerant KRAS-mutant cancer cells. [PDF]

Commun Biol
Furukawa H, Umezawa K, Sun Y, Chiba H, Kubonishi M, Naito H, Miura Y, Ito K, Aoki S.   +8 more
europepmc   +1 more source